Who is sponsoring NCT05219266?

NCT05219266 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05219266?

Interventions in NCT05219266: midostaurin.

What condition does NCT05219266 study?

NCT05219266 studies FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia, Acute Myeloid Leukemia, Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis With an Associated Hematologic Neoplasm.

Is NCT05219266 still recruiting?

NCT05219266 is currently no longer available. Last updated 28 June 2024.

Last reviewed 2024-06-28 · How we verify

NCT05219266

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Managed Access Programs for PKC412, Midostaurin

NO LONGER AVAILABLE Last updated 28 June 2024

What this trial tests

trial testing midostaurin in FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia. No longer available.

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS

Drugs / interventions tested

midostaurin (MIDOSTAURIN) — full drug profile →

Conditions studied

FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia — all drugs for FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia →
Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Aggressive Systemic Mastocytosis — all drugs for Aggressive Systemic Mastocytosis →
Mast Cell Leukemia — all drugs for Mast Cell Leukemia →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with FMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid Leukemia or Acute Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this registration is to list Managed Access Programs (MAPs) related to PKC4, Midostaurin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of midostaurin

Trials testing the same drug.

NCT03760445 — HDM201 Added to CT in R/R or Newly Diagnosed AML · Phase 1, PHASE2 · withdrawn

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05219266 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 28 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05219266.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing